Linaclotide is a minimally absorbed guanylate cyclase-C agonist. The objective of this trial was to determine the effi cacy and safety of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C).
INTRODUCTION
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder characterized by frequent and intermittent episodes of abdominal pain and abdominal discomfort that are associated with altered bowel habits ( 1, 2 ) . Th e symptoms of IBS not only adversely aff ect a patient ' s health-related quality of life ( 3 ) but also place a signifi cant fi nancial burden on society due to reduced work productivity and increased use of healthcare-related resources ( 4, 5 ) . IBS with constipation (IBS-C) aff ects approximately one-third of IBS patients ( 3 ) , occurs more commonly in women than men ( 6 ) , and frequently includes additional symptoms, such as abdominal bloating, hard stools, straining, and sensation of incomplete evacuation ( 7, 8 ) .
Traditional therapies for IBS-C, generally directed towards the patient ' s predominant symptoms ( 9 ) , are frequently associated with patient dissatisfaction ( 10 ) . More recent therapies, including tegaserod and lubiprostone, have been shown to improve global symptoms of IBS-C ( 9 ) . Tegaserod, a 5-HT 4 partial agonist approved by the Food and Drug Administration (FDA) for the short-term treatment of women with IBS-C, was removed from the market in 2007 due to increased cardiovascular events in patients receiving the medication. Lubiprostone, a chloride channel activator that was approved by the FDA for the treatment of women with IBS-C in 2008, has shown effi cacy using a global end point (global symptom relief) ( 11 ) . Given the limited treatments currently available for patients with IBS-C, additional therapeutic options would be of value.
Linaclotide, a minimally absorbed 14-amino-acid peptide structurally related to the endogenous guanylin peptide family of hormones that regulate fl uid and electrolyte homeostasis in the intestine, binds to and activates GCC (guanylate cyclase-C) on the luminal surface of the intestinal epithelium. Activation of GCC results in the generation of cyclic guanosine monophosphate (cGMP), which is increased in both the intracellular and extracellular compartments. Th e increase in cGMP within intestinal epithelial cells triggers a signal transduction cascade activating the cystic fi brosis transmembrane conductance regulator ( 12 ) . Th is activation causes secretion of chloride and bicarbonate into the intestinal lumen; sodium ions and water follow, resulting in increased luminal fl uid secretion and a refl ex acceleration of intestinal transit. Extracellular cGMP, actively transported out of intestinal epithelial cells, is believed to reduce visceral hyperalgesia by modulating the activity of aff erent pain fi bers ( 13 ) . In animal models, linaclotide treatment accelerated gastrointestinal transit and reduced visceral nociception ( 14 ) ; in human phase 2 clinical studies, it accelerated colonic transit ( 15 ) and improved abdominal pain and constipation associated with IBS-C ( 16 ) . Likewise, in two large phase 3 trials in patients with chronic constipation, linaclotide signifi cantly improved bowel and abdominal symptoms over 12 weeks ( 17 ) .
Th e objective of this phase 3 clinical trial was to assess the effi cacy and safety of linaclotide administered once daily as an oral capsule at a dose of 290 μ g vs. placebo to patients with IBS-C. A 4-week randomized withdrawal (RW) period was included in this trial to assess the eff ect of discontinuing treatment with linaclotide.
METHODS

Trial design
Th is multicenter, randomized, double-blind, placebo-controlled, parallel-group trial was conducted at 118 outpatient clinical research centers (111 in the United States, 7 in Canada) from 14 July 2009 (fi rst patient enrolled) to 12 July 2010 (last patient completed). Th e protocol and all trial procedures were approved by an Institutional Review Board, and the trial was designed, conducted, and reported in accordance with the principles of Good Clinical Practice guidelines. All patients gave written informed consent before their participation in the trial.
Aft er a screening period of up to 21 days followed by a pretreatment baseline period of 14 -21 days, eligible patients were randomly assigned with the use of an interactive voice-response system (IVRS) to receive once daily an oral capsule of either linaclotide 290 μ g or placebo, in a 1:1 ratio. Patients who completed all 12 weeks of the double-blind treatment period were eligible to enter the double-blind 4-week RW period in which patients initially randomized to linaclotide were re-randomized (1:1) to linaclotide 290 μ g or placebo, and patients previously randomized to placebo were assigned to receive linaclotide 290 μ g once a day. Randomization assignments were generated in blocks of four and stratifi ed according to trial center. All sponsor staff involved in the trial, trial center personnel, and patients were blinded to the allocation of trial treatment. Trial visits were conducted at screening, at the start of the pretreatment baseline period, at randomization (day 1), throughout the treatment period (weeks 2, 4, 8, and 12), and at the beginning and end of the RW period (weeks 13 and 16 (end of trial)). Patients made daily calls to the IVRS to report their symptoms throughout the trial.
Trial patients
Female and male patients were eligible to participate if they were at least 18 years of age, and met modifi ed Rome II criteria for IBS ( 18 ) . In the 12 months before the screening visit, eligible patients were to have for at least 12 weeks, which need not be consecutive, abdominal pain, or abdominal discomfort that had ≥ 2 of these three features: (i) relieved with defecation, (ii) onset associated with a change in frequency of stool, and (iii) onset associated with a change in form (appearance) of stool, before starting chronic treatment with tegaserod or lubiprostone (if patients had taken these medications); and < 3 spontaneous bowel movements (SBMs) per week (SBM = a bowel movement (BM) occurring in the absence of any laxative, suppository, or enema use during the preceding 24 h), and had at least one additional bowel symptom (straining, lumpy or hard stools, and sensation of incomplete evacuation during > 25 % of BMs), before starting chronic treatment with tegaserod, lubiprostone, polyethylene glycol 3350, or any laxative (if patients had taken these medications). In addition, patients had to report an
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average score ≥ 3.0 for daily abdominal pain at its worst (11-point NRS (numerical rating scale)) as well as an average of < 3 complete SBMs (CSBMs) per week (CSBM = an SBM associated with a sense of complete evacuation, as reported by the patient) and ≤ 5 SBMs per week during the 14 days immediately before randomization (i.e., the baseline period).
Patients were excluded if they reported loose (mushy) or watery stools for > 25 % of their BMs during the 12 weeks before screening or, during the baseline period, a BSFS (Bristol Stool Form Scale) ( 19 ) score of 7 (watery, no solid pieces) for any SBM, or a BSFS score of 6 (fl uff y pieces with ragged edges, a mushy stool) for > 1 SBM. Other key exclusion criteria included history of cathartic colon, laxative or enema abuse, ischemic colitis, or pelvic fl oor dysfunction (unless successful treatment had been documented by a normal balloon expulsion test); bariatric surgery for treatment of obesity or surgery to remove a segment of the gastrointestinal tract at any time before the screening visit, surgery of the abdomen, pelvis, or retroperitoneal structures during the 6 months before the screening visit, appendectomy or cholecystectomy during the 60 days before the screening visit, or other major surgery during the 30 days before the screening visit; history of diverticulitis or any chronic condition that could be associated with abdominal pain or discomfort and could confound the assessments in the trial (e.g., infl ammatory bowel disease, chronic pancreatitis, polycystic kidney disease, ovarian cysts, endometriosis, lactose intolerance); family history of a familial form of colorectal cancer. In general, patients were excluded if they were taking drugs that could cause constipation (e.g., narcotics); however, patients taking certain drugs for IBS that might be constipating (e.g., tricyclic antidepressants) were eligible provided that they were on a stable dose for at least 30 days before the screening visit and there was no plan to change the dose aft er the screening visit. Colonoscopy requirements were based on the American Gastroenterological Association guidelines ( 20 ) . Women of childbearing potential were required to use contraceptives and have a negative serum pregnancy test. Patients were asked to refrain from making any major lifestyle changes (e.g., starting a new diet or changing their exercise pattern) during the trial.
Rescue medication (bisacodyl 5 mg tablet or 10 mg suppository) was allowed for severe constipation (i.e., 72 h aft er the patient ' s previous BM or when symptoms became intolerable). Use of rescue medication was not allowed on the day before, the day of, and the calendar day aft er the randomization visit. Patients on a stable, continuous regimen of fi ber, bulk laxatives, stool soft eners, or probiotics during the 30 days before the screening visit were allowed to continue, provided they maintained a stable dosage throughout the trial.
Effi cacy assessments and end points
Daily reports by patients to IVRS included symptom ratings of worst abdominal pain, abdominal discomfort, abdominal cramping, abdominal fullness, and abdominal bloating (all abdominal symptoms were measured using an 11-point NRS), as well as the number of BMs and whether rescue medication was used.
Each BM was assessed for sensation of complete bowel emptying (yes / no), stool consistency (7-point BSFS with 1 = " separate hard lumps like nuts " to 7 = " watery, no solid pieces " ), and severity of straining (5-point ordinal scale). Weekly IVRS assessments included IBS severity and constipation severity (both using a 5-point ordinal scale), degree of IBS relief (7-point balanced scale), and adequate relief of IBS-C symptoms (yes / no). Assessment of satisfaction with the trial-medication ' s ability to relieve IBS symptoms (5-point ordinal scale) was captured at all study visits following randomization.
Primary end points . Th ere were four prespecifi ed primary end points in the trial, which were all responder end points. One of the four primary end points was based on the FDA recommendations for IBS-C trial design and end points in the recently fi nalized guidance for IBS clinical trials (May 2012) ( 21 ); a responder for this end point (to be referred to hereaft er as " FDA end point " ) was defi ned as a patient who met both of the following criteria in the same week for at least 6 of the 12 weeks of the treatment period: (i) an improvement of ≥ 30 % from baseline in the average of the daily worst abdominal pain scores (to be referred to hereaft er as " abdominal pain " ) and (ii) an increase of ≥ 1 CSBM from baseline. Th is combined end point was added aft er the initiation of the trial, but before completion of enrollment and database lock, with a protocol amendment (no unblinding had occurred). Th e other three primary end points also required patients to meet weekly responder defi nitions, but for at least 9 of the 12 weeks of the treatment period. Th ese weekly responder defi nitions were (i) an improvement of ≥ 30 % in abdominal pain, (ii) ≥ 3 CSBMs and an increase of ≥ 1 CSBM from baseline, and (iii) a combined end point that defi ned a responder as a patient who met criteria for both i and ii in the same week.
Secondary end points . Th e secondary end points included 12-week change from baseline in abdominal pain, abdominal discomfort, abdominal bloating, stool frequency (CSBM and SBM weekly rates), stool consistency (BSFS), and severity of straining; secondary responder end points included abdominal pain and CSBM responders (using the individual components of the FDA end point). A number of other additional end points were also assessed, including 12-week change from baseline in abdominal fullness and abdominal cramping, IBS symptom severity, constipation severity, adequate relief of IBS-C symptoms, degree of relief of IBS symptoms, and treatment satisfaction.
Safety assessments
At each scheduled study visit, all patients were asked an openended question regarding adverse events (AEs). Patients reported AEs by recalling instances since the prior visit. Th e site investigator assessed all patient-reported AEs and judged each event for severity and relationship to the blinded trial medication. Other safety evaluations included physical examinations, electrocardiogram recordings, vital sign measurements, and standard clinical laboratory tests. 
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Pharmacokinetic assessments
During the treatment period, a subset of patients had blood samples taken at the randomization and week 4 visits to determine if linaclotide or its active metabolite, MM 419447, could be detected at quantifi able levels in the plasma.
Statistical methods and data analysis
Th e overall family-wise type I error rate for testing the primary and secondary effi cacy end points was controlled at the 0.05 signifi cance level using a fi ve-step serial gate-keeping, multiple-comparison procedure. Based on this multiple-comparison procedure and the results of a previous phase 2b study ( 16 ) , a sample size of 400 patients per treatment arm was selected to provide >85 % overall power to simultaneously detect a diff erence between the placebo and linaclotide groups for the primary end points.
Responder end points were analyzed using a CochranMantel -Haenszel (CMH) test controlling for geographic region. Continuous change-from-baseline end points were analyzed using an ANCOVA (analysis of covariance) model with fi xed-eff ect terms for treatment group and geographic region and the corresponding baseline value as a covariate. Least-squares means (i.e., means adjusted for the other eff ects) from the ANCOVA model based on patients ' overall average scores (except for SBMs and CSBMs, for which the overall weekly rates were calculated) are presented. Geographic region was used as a factor in the analyses rather than individual trial centers due to the potential for very small numbers of patients at some trial centers.
If a patient dropped out of the trial or otherwise did not report effi cacy data for a particular treatment-period week (patients were required to complete at least four IVRS calls during a treatment week), the patient was not considered a responder for that week. An observed-cases approach to missing data was applied to the change-from-baseline secondary end points, such that if a patient dropped out of the trial or otherwise did not report data, the average of the non-missing data over the 12 weeks of the treatment period was the patient ' s value. Patients were assumed to have not had BMs nor taken rescue medication if the corresponding daily
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which required improvement in abdominal pain (i.e., a reduction of ≥ 30 % in abdominal pain), CSBM rate (i.e., ≥ 3 CSBMs and an increase of ≥ 1 CSBM), or both for at least 9 of the 12 weeks of the treatment period ( Table 2 ) . Th e NNT (number needed to treat) for the primary end points ranged from 7.6 to 14.3. question was not answered. For the analysis of adequate relief, degree of relief of IBS symptoms, and treatment satisfaction, a last observation carried forward method was used. All P values were based on two-sided tests.
All randomized patients who took at least one dose of trial medication were included in safety analyses (safety population). Effi cacy analyses were based on the ITT (intent-to-treat) population, which included all patients in the safety population who had at least one post-randomization entry of the primary effi cacy assessment (i.e., IVRS assessment of abdominal pain or CSBMs).
RESULTS
Patient disposition, demographics, and baseline characteristics
Of the 2,424 patients who were screened for participation in this trial, 803 (33 % ) were randomized to treatment ( Figure 1 ). Two patients were randomized at more than one trial center but only data from the trial center in which they were fi rst randomized were included in statistical analyses. Of the 802 patients who received double-blind trial medication (safety population), 800 patients had at least one post-randomization entry of the primary effi cacy assessment (ITT population). Th e demographics of the ITT population are shown in Table 1 . Following completion of the treatment period, a total of 647 (81 % ) ITT patients entered the RW period of the trial, of which 645 received at least one dose of trial medication and were included in the RW population. Mean compliance with the trial-medication dosing (assessed by counting pills returned at trial visits) up to trial discontinuation / completion of the 12-week treatment period was 95 and 94 % for the placebo and linaclotide groups, respectively. Compliance with the daily IVRS call-in (patients who completed ≥ 80 % of scheduled calls) during the treatment period was 73 and 71 % for placebo-and linaclotide-treated patients, respectively. During the pretreatment baseline period, 88 % of patients experienced abdominal pain every day and 76 % of patients had no CSBMs.
Effi cacy results
For all primary and secondary effi cacy end points, the linaclotide 290-μ g group demonstrated statistically signifi cant improvement compared with the placebo group, controlling for multiplicity.
For the individual components of the FDA end point, a significantly greater percentage of linaclotide-treated patients, compared with placebo-treated patients, reported a reduction of ≥ 30 % in abdominal pain for at least 6 out of the 12 weeks of the treatment period (50.1 vs. 37.5 % , P = 0.0003 ( Figure 2 ) ) or an increase of ≥ 1 CSBM from baseline for at least 6 out of the 12 weeks of the treatment period (48.6 vs. 29.6 % , P < 0.0001 ( Figure 2 ) ). A total of 136 of 405 patients (33.6 % ) receiving linaclotide compared with 83 of 395 patients (21.0 % ) receiving placebo (odds ratio: 1.9, 95 % confi dence interval: 1.4, 2.7; P < 0.0001) met the FDA end point ( Table 2 ; Figure 2 ) . A signifi cantly greater percentage of linaclotide-treated patients than placebo-treated patients also met the responder requirements for the other three primary end points, Assessed using the BSFS: 1=separate hard lumps, like nuts (hard to pass); 2=sausage-shaped, but lumpy; 3=like a sausage but with cracks on its surface; 4=like a sausage or snake, smooth and soft; 5=soft blobs with clear cut edges (passed easily); 6=fl uffy pieces with ragged edges, a mushy stool; 7=watery, no solid pieces (entirely liquid).
c Assessed using a 5-point ordinal scale: 1=not at all; 2=a little bit; 3=a moderate amount; 4=a great deal; 5=an extreme amount.
d Assessed using a 5-point ordinal scale: 1=none; 2=mild; 3=moderate; 4=severe; 5=very severe. All demographic characteristics were similar between treatment groups. For baseline clinical characteristics, signifi cant differences were observed for abdominal fullness ( P =0.011), stool consistency ( P =0.046), and straining ( P =0.020).
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Linaclotide in IBS-C Linaclotide-treated patients also experienced statistically signifi cantly greater improvements compared with placebo-treated patients for the secondary and additional end points ( Table 3 ) . During the fi rst week of treatment and for each subsequent week of treatment, linaclotide-treated patients reported greater improvements in worst abdominal pain and CSBM frequency compared with placebo-treated patients ( P < 0.001; Figure 3 ). At week 12, the mean decrease from baseline in worst abdominal pain was 2.4 % for linaclotide vs. 1.5 % for placebo ( P < 0.0001), and the mean increase from baseline in the weekly CSBM rate was 2.4 and 0.9 for linaclotide and placebo, respectively ( P < 0.0001). At the end of the Treatment Period (week 12), 52 % of linaclotide-treated patients 
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Linaclotide in IBS-C were either " very satisfi ed " or " quite satisfi ed " with treatment compared with 23 % of placebo-treated patients ( P < 0.0001). During the 4-week RW Period, patients who were re-randomized from linaclotide to placebo showed an increase in worst abdominal pain and a decrease in CSBMs to levels similar to those observed in the placebo group during the Treatment Period. Th e patients who continued to take linaclotide showed sustained improvement in worst abdominal pain and CSBMs similar to that previously observed during the Treatment Period. Th ese improvements were statistically signifi cant compared to patients re-randomized to placebo for weeks 13 -16 for CSBMs ( P < 0.001) and weeks 14 -16 for worst abdominal pain ( P < 0.05). Patients who switched from placebo to linaclotide showed levels of improvement similar to those experienced by linaclotide-treated patients during the Treatment Period ( Figure 3 ).
Safety
A total of 228 of 406 linaclotide-treated patients (56.2 % ) reported at least one treatment-emergent AE (TEAE) compared with 210 of 396 placebo-treated patients (53.0 % ) in the 12-week treatment period ( Table 4 ). Most TEAEs were mild or moderate in severity (93.8 % , linaclotide; 98.1 % , placebo). Th e incidences of diarrhea ( P < 0.0001), fl atulence ( P = 0.0084), and abdominal pain ( P = 0.0462) TEAEs were signifi cantly greater in the linaclotide-treated patients compared with placebo-treated patients. Th e most common TEAE in the 12-week treatment period was diarrhea, experienced by 19.5 % of linaclotide-treated patients compared with 3.5 % of placebo-treated patients. Th e occurrences of diarrhea were reported to be mild or moderate in 71 of 79 linaclotide-treated patients (89.9 % ) and 13 of 14 placebotreated patients (92.9 % ) who experienced diarrhea. Th ere were no SAEs of diarrhea reported during the trial. None of the patients who reported diarrhea experienced clinically signifi cant sequelae (e.g., orthostatic hypotension or dehydration). More than half of linaclotide-treated patients who experienced diarrhea had onset within the fi rst 2 weeks of treatment. Diarrhea was the most common AE resulting in treatment discontinuation in linaclotidetreated patients (5.7 vs. 0.3 % in placebo-treated patients); overall, AEs resulted in the premature discontinuation of 32 patients (7.9 % ) and 11 patients (2.8 % ) taking linaclotide and placebo, respectively, in the treatment period.
Rates of serious AEs (SAEs) did not diff er between linaclotide and placebo groups (two patients in each group (0.5 % )). In the linaclotide group, the SAEs consisted of one patient who experienced chronic cholecystitis and a second patient who experienced duodenitis, gastroenteritis, hiatal hernia, esophagitis, renal cyst, and urinary tract infection. Th ere were no deaths during the treatment period; one screened patient died as a result of cardiorespiratory arrest and ventricular fi brillation due to a possible drug overdose, but this patient died before randomization and did not receive trial medication.
Th ere were no clinically signifi cant diff erences between the linaclotide and placebo groups in the incidence of abnormal laboratory parameters, vital signs, or electrocardiogram parameters. Serum bicarbonate levels were below the lower limit of normal at the end of treatment in seven patients receiving linaclotide compared with one patient receiving placebo. None of these patients reported diarrhea as an AE or other AEs that were considered to be related to low bicarbonate levels.
In the subset of patients who were assessed for linaclotide exposure, no quantifi able plasma levels of linaclotide were detected following trial-medication dosing at the randomization and week 4 trial visits. All patients tested (72 placebo and 64 linaclotide) had levels lower than the limit of quantifi cation for linaclotide ( < 0.2 ng / ml) and its primary metabolite, MM-419447 ( < 2.0 ng / ml). experienced asthma and a second patient who experienced pericardial eff usion and pericarditis leading to withdrawal from the trial. In the placebo group, the SAEs consisted of one patient who Weekly results for complete spontaneous bowel movement (CSBM) frequency ( a , * P < 0.0001 for linaclotide patients compared with placebo patients for each of the 12 Treatment-Period weeks, * * P < 0.001 for linaclotide -linaclotide patients compared with linaclotide -placebo patients for RW Period weeks 13 -16); reduction in worst abdominal pain ( b , * P < 0.001 for linaclotide patients compared with placebo patients for each of the 12 Treatment Period weeks, * * P < 0.05 for linaclotide -linaclotide patients compared with linaclotide -placebo patients for RW Period weeks 14 -16); and percent reduction in worst abdominal pain ( c , * P < 0.001 for linaclotide patients compared with placebo patients for each of the 12 Treatment Period weeks, * * P < 0.05 for linaclotide -linaclotide patients compared with linaclotide -placebo patients for RW Period week 14).
All P values were derived from an analysis of covariance model.
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During the RW period, TEAEs occurred in 22.2 % of linaclotide -linaclotide patients, 22.1 % of linaclotide -placebo patients, and 30.6 % of placebo -linaclotide patients. With the exceptions of diarrhea and abdominal pain, the incidence of TEAEs was similar across the three treatment sequences. Th e incidence of diarrhea was 1.9, 0.6, and 11.7 % , in linaclotide -linaclotide, linaclotideplacebo, and placebo -linaclotide patients, respectively. Th e incidence of abdominal pain was 1.3 % in the linaclotide -linaclotide patients and 2.4 % in the placebo -linaclotide patients; there were no TEAEs of abdominal pain in the linaclotide -placebo patients. Th ere was no evidence of " rebound " (i.e., worse ning in IBS-C symptoms compared with the baseline period in the linaclotide -placebo patients). No SAEs were reported during the RW period.
DISCUSSION
In this large phase 3 clinical trial, a greater percentage of IBS-C patients who were treated with linaclotide achieved statistically signifi cant improvement in the key symptoms of IBS-C, including abdominal pain and constipation, compared with placebo. Four primary outcomes measures were assessed, including the FDA end point. Th is end point required that patients experience a benefi t of at least 30 % when compared with baseline in abdominal pain and an increase of ≥ 1 CSBM from baseline in the same week for at least 6 out of the 12 weeks of the treatment period. In spite of the rigor of this end point, 33.6 % of linaclotide-treated patients were responders compared with 21.0 % of placebo-treated patients ( P < 0.0001). Furthermore, statistically signifi cant diff erences in responder rates were also demonstrated for the three other primary end points, which required (i) a decrease in abdominal pain of ≥ 30 % , (ii) both an absolute value of ≥ 3 CSBMs and an increase of ≥ 1 CSBM from baseline, and (iii) both abdominal pain and CSBM criteria for at least 9 of the 12 weeks of the treatment period.
Although IBS is a disorder with multiple symptoms, abdominal pain is one of the cardinal manifestations and strongly correlates with IBS severity ( 22 ) and utilization of healthcare resources ( 23 ) . Also, an improvement in abdominal pain of ≥ 30 % has been shown to be clinically important in IBS patients ( 23 ) , and in patients reporting pain relief in general ( 24 ) . In this trial, more than half of linaclotide-treated patients reported an improvement in abdominal pain of ≥ 30 % for at least 6 out of 12 weeks compared with 37.5 % of placebo-treated patients, for an NNT of 7.9. Improvement in abdominal pain began within the fi rst week of therapy, and once reaching maximum at 6 -8 weeks, was sustained throughout the remainder of the treatment period. By the last week of the treatment period (week 12), linaclotide-treated patients reported a mean improvement of 43.2 % in abdominal pain compared with 27.5 % for placebo-treated patients. During the 4-week RW period, patients re-randomized to remain on linaclotide had continued relief of abdominal pain, showing durability of response, while those re-randomized from linaclotide to placebo showed a gradual worsening of abdominal pain symptoms to the level experienced by patients receiving placebo during the treatment period, but without signs of a " rebound " or worsening of symptoms relative to baseline.
In addition to abdominal pain, linaclotide improved several other important abdominal symptoms that are frequently reported by IBS-C patients, including abdominal bloating and abdominal discomfort, beginning during the fi rst week of treatment and continuing throughout the 12-week treatment period. Linaclotide also improved bowel function, including SBM and CSBM frequency, straining, stool consistency, and constipation severity. However, in contrast to the gradual improvement in abdominal symptoms, improvement in bowel function occurred more rapidly. Most linaclotide-treated patients experienced an SBM within 24 h of the fi rst dose of linaclotide (67.4 vs. 43.8 % for placebo, P < 0.0001); maximal improvement in bowel function usually occurred within the fi rst week. Th us, improvement with linaclotide in abdominal (sensory) symptoms such as abdominal pain may be attributable to more than improvement in bowel function alone. Preclinical data suggest that cGMP, which is released intra-and extracellularly following GCC activation by linaclotide, can reduce the fi ring of pain-sensing visceral aff erent fi bers ( 13 ) . Further studies are under way that may provide a better understanding of the mechanisms by which linaclotide exerts its benefi cial eff ects directly on abdominal sensory symptoms.
Diarrhea was the most common TEAE in linaclotide-treated patients and appears to be an extension of linaclotide ' s pharmacological eff ects. Although diarrhea was reported in 19.5 % of linaclotide-treated patients, only 2 % reported that they had severe diarrhea and only 5.7 % discontinued the drug due to diarrhea. Th e incidence of SAEs was similar between linaclotideand placebo-treated patients ( n = 2 patients in each group); diarrhea was not reported as an SAE.
In conclusion, linaclotide signifi cantly improved abdominal and bowel symptoms in this phase 3 trial (12-week treatment period + 4-week RW period).
